University of North Carolina at Chapel Hill

Parion Sciences, Inc.

Other

Molichem Medicines, Inc.

University of Missouri

Inspire Pharmaceuticals, Inc.

Burroughs Wellcome Co.

Research, Incorporated

Richard C Boucher

Michael Ross Johnson

Monroe Jackson Stutts

William Robert Thelin

Janet L Rideout

Benjamin R Yerxa

William Pendergast

David C Henke

Luis Miguel Molina Y Vedia

Andrew J Hirsh

Eduardo R Lazarowski

Sammy Ray Shaver

Karla M Jacobus

Robert P Dougherty

Tomas Navratil

Kevin D Lustig

Wanda Kay O'Neal

Thomas K Harden

Barbara Grubb

Marcus Mall

Cara A Geary

Laura J Erb

Daniel M Sullivan

Claude E Parr

John T Turner

Gary A Weisman

Brian Button

Dallas Croom

David J Drutz

Michael K James

Michael R Knowles

Jianzhong Zhang

Michael Royce Johnson

James B Fink

Anthony James Hickey

Mark Jeffrey Edhouse

Christy L Shaffer

Philip Jerome Driver

Stuart Robert Abercrombie

Cary Geary

M Jackson Stutts

Paul Boucher

Maryse Picher

Nicholas O Heijne

Donal Joseph Taylor

Jonathan Hugh Wilkins

John T Gatzy

Cara Geary

Edwardo R Lazarowski

Brian M Button

William R Thelin

Andrew J Hirch

Sodium channel blockers represented by the formula: are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.

Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases

Embodiments disclosed herein are directed to methods, compositions and apparatus for administering active agents to the lungs of a subject.

Methods of treatment

The invention described herein is directed to method of treating chronic obstructive pulmonary disease, comprising administering an effective amount of an osmolyte by at least one nasal cannula to a subject in need thereof. Also provided is a nasal cannula system for delivering an osmolyte, comprising a nebulizer and tubing having two ends, where the first end of the tubing is connected to the nebulizer and the second end of the tubing is tapered to fit in the nostril of a subject.

Inhaled hypertonic saline delivered by a heated nasal cannula

Provided are methods of treating a variety of disorders of the skin with inhibitors of the epithelial sodium channel (ENaC). The inhibitors are represented by formula (I)-(IV): where R is defined herein.

Sodium channel blockers for skin disorders

A nonhuman transgenic mammal is described whose genome comprises a promoter construct operably linked to a heterologous DNA encoding an epithelial sodium channel &#x3b2; subunit, wherein said promoter construct directs expression of the epithelial sodium channel &#x3b2; subunit in lung epithelial cells of said animal, and wherein said transgenic mammal has increased lung mucus retention as compared to the corresponding wild-type mammal. The animal is useful in screening compounds for activity in treating lung diseases such as cystic fibrosis and chronic obstructive pulmonary disease.

Animal model for chronic obstructive pulmonary disease and cystic fibrosis

An aerosol preparation assembly includes an entrainment chamber defining an entrainment volume. The entrainment chamber includes a gas inlet port, an aerosol inlet port and an outlet port. The entrainment chamber is configured such that a velocity of a flow of a gas within the entrainment volume is less than a velocity of the flow of the gas within the gas inlet port. The entrainment chamber is configured such that at least a portion of inlet aerosol is entrained into the flow of the gas within the entrainment volume to produce an entrained aerosol flow at the outlet port. The particle selection chamber is configured to receive the entrained aerosol flow and produce an outlet aerosol flow. The particle selection chamber and nozzle are collectively configured such that a volumetric median diameter of the outlet aerosol flow is less than a volumetric median diameter of the inlet aerosol.

Aerosol delivery systems, compositions and methods

The present invention concerns methods, compositions and apparatus for administering active agents to the lungs of a subject.

The present invention relates to blocking salt taste using compounds of Formula I as defined herein.

Pyrazinoylguanidine compounds for use as taste modulators

Provided is class of sodium channel blockers. One example of such a compound is shown by the following formula: The compounds are useful for promoting hydration of mucosal surfaces and treating a variety of disease conditions.

Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity

The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.

Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes

Growing community of inventors

Chapel Hill, NC, United States of America

Richard C Boucher